Add Claims 104-127.

104. (New) A pharmaceutically acceptable formulation comprising FSH or FSH variant and benzyl alcohol in an aqueous diluent.

105. (New) A pharmaceutically acceptable formulation suitable for multi-dose comprising FSH or FSH variant and benzyl alcohol in an aqueous diluent.

106. (New) A pharmaceutically acceptable formulation comprising FSH or FSH variant and benzyl alcohol in an aqueous diluent, wherein the heterodimer content is sufficiently stable to provide a multi-dose pharmaceutical product.

107. (New) A pharmaceutically acceptable formulation comprising FSH or FSH variant and benzyl alcohol in an aqueous diluent, wherein the rate of heterodimer loss at room temperature is about the same in the formulation as in a control formulation lacking benzyl alcohol.

108. (New) The formulation of Claim 104, wherein the FSH is human FSH.

109. (New) The formulation of Claim 105, wherein the FSH is human FSH.

110. (New) The formulation of Claim 106, wherein the FSH is human FSH.

111. (New) The formulation of Claim 107, wherein the FSH is human FSH.

112. (New) The formulation of Claim 104 comprising an FSH variant of the formula:

α-subunit: (SEQ ID NO:5)

APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSEST
CCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
ß-subunit: (SEQ ID NO:11)

NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELV
YETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGE.

113. (New) The formulation of Claim 105 comprising an FSH variant of the formula:

α-subunit: (SEQ ID NO:5)

APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSEST
CCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
ß-subunit: (SEQ ID NO:11)

NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELV
YETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGE.

114. (New) The formulation of Claim 106 comprising an FSH variant of the formula:

α-subunit: (SEQ ID NO:5)

APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSEST
CCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
ß-subunit: (SEQ ID NO:11)

NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELV
YETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGE.

115. (New) The formulation of Claim 107 comprising an FSH variant of the formula:

α-subunit: (SEQ ID NO:5)

APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSEST
CCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
ß-subunit: (SEQ ID NO:11)

NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELV
YETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGE.

116. (New) The formulation one of Claim 104, wherein the FSH or FSH variant is urinary FSH.

117. (New) The formulation one of Claim 105, wherein the FSH or FSH variant is urinary FSH.

118. (New) The formulation one of Claim 106, wherein the FSH or FSH variant is urinary FSH.

119. (New) The formulation one of Claim 107, wherein the FSH or FSH variant is urinary FSH.

120. (New) The formulation of Claim 104, wherein the FSH or FSH variant is produced through the use of recombinant DNA technology.

121. (New) The formulation of Claim 105, wherein the FSH or FSH variant is produced through the use of recombinant DNA technology.

122. (New) The formulation of Claim 106, wherein the FSH or FSH variant is produced through the use of recombinant DNA technology.

Cont 1

123. (New) The formulation of Claim 107, wherein the FSH or FSH variant is produced through the use of recombinant DNA technology.

124. (New) The formulation of Claims 104, wherein the FSH or FSH variant is at a concentration of 50 μg/mL to about 200 μg/mL.

125. (New) The formulation of Claims 105, wherein the FSH or FSH variant is at a concentration of 50 μg/mL to about 200 μg/mL.

126. (New) The formulation of Claims 106, wherein the FSH or FSH variant is at a concentration of 50 μg/mL to about 200 μg/mL.

127. (New) The formulation of Claims 107, wherein the FSH or FSH variant is at a concentration of 50 μg/mL to about 200 μg/mL.